We are analyzing https://link.springer.com/article/10.1007/s007020050026.

Title:
CSF copper concentrations, blood-brain barrier function, and coeruloplasmin synthesis during the treatment of Wilson's disease | Journal of Neural Transmission
Description:
Journal of Neural Transmission - During the treatment of four patients with cerebral manifestation of Wilson
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Telecommunications
Health & Fitness
Science

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We see no obvious way the site makes money.

Not all websites are made for profit; some exist to inform or educate users. Or any other reason why people make websites. And this might be the case. Link.springer.com might be making money, but it's not detectable how they're doing it.

Keywords {🔍}

copper, article, csf, concentration, disease, serum, initial, bloodbrain, barrier, treatment, wilsons, patients, privacy, cookies, content, journal, albumin, ratio, therapy, average, access, function, information, publish, search, coeruloplasmin, measured, months, month, neurological, data, log, research, neural, stuerenburg, brain, related, discover, springer, optional, personal, parties, policy, find, track, transmission, concentrations, synthesis, march, volume,

Topics {✒️}

blood-brain barrier region blood-brain barrier function cerebrospinal fluid copper-related toxic effects month download article/chapter blood-brain barrier blood-brain-barrier csf copper half-life serum copper half-life privacy choices/manage cookies neural transmission aims csf copper concentrations full article pdf albumin ratio csf/serum free copper concentration european economic area scope submit manuscript urinary copper excretion csf copper concentration related subjects conditions privacy policy initial copper concentration accepting optional cookies article stuerenburg journal finder publish serum coeruloplasmin concentration article journal march 2000 volume 107 half – life wilson disease patients article log brain volume copper concentration 1007/s007020050026 keywords privacy policy personal data neural transm 107 brain toxicity information disease published initial values books a article cite check access instant access optional cookies manage preferences normal concentration mobilized copper copper overload

Schema {🗺️}

WebPage:
      mainEntity:
         headline:CSF copper concentrations, blood-brain barrier function, and coeruloplasmin synthesis during the treatment of Wilson's disease
         description: During the treatment of four patients with cerebral manifestation of Wilson's disease, we measured the copper concentration in the cerebrospinal fluid (CSF) and serum, the serum coeruloplasmin concentration, the free copper concentration in the serum, and the albumin ratio CSF/serum (AR). These measurements were treated as indicators of the copper-related toxic effects on the brain and the blood-brain barrier (BBB). The half – life of the decrease in the CSF copper concentration during therapy was 23.5 ± 5.78 months (mean ± S.E.M.). The therapeutic – target – copper concentration in the CSF (mean normal concentration) is below 20 μg/l. The average length of therapy needed to normalize CSF – copper values in our patients with an average initial value of 76.25 μg/L was 47 month. During the first 10 month of treatment there was an increase in all cases of the measured disturbance in the blood-brain barrier (measured as the ratio of albumin in CSF to albumin in serum, AR). All patients showed an initial worsening of the neurological condition, on average after 1.75 ± 0.25 months. The maximal rise in AR, from the initial values, was on average 18.4 ± 5.08%; this maximum was reached after an average of 6.9 ± 1.5 months. The AR normalized during therapy, indicating a reduction in toxicity in the blood-brain barrier region. The extent of the AR increases in individual patients did not correlate significantly with CSF copper half-life, serum copper half-life, the initial half – life of the reduction in the ratio (copper in serum)/(coeruloplasmin in serum), the initial copper concentration in CSF or serum, the initial free copper concentration in serum, or the initial dose of penicillamine (within the first 2 months). We conclude that the normalization of the CSF copper concentration in patients with the cerebral manifestation of Wilson's disease is a slow process, even if therapy is sufficient. The initial worsening of the neurological condition which has often been reported may be reflected in the disturbance of blood-brain barrier function, which we have measured here for the first time (using the parameter of the albumin ratio CSF/serum). Based on repeated measurements of the AR during the course of treatment it seems that the brain toxicity of mobilized copper can be assessed and the therapy adjusted.
         datePublished:
         dateModified:
         pageStart:321
         pageEnd:329
         sameAs:https://doi.org/10.1007/s007020050026
         keywords:
            Keywords: Wilson's disease, copper, coeruloplasmin, blood-brain-barrier, albumin ratio.
            Neurology
            Psychiatry
            Neurosciences
         image:
         isPartOf:
            name:Journal of Neural Transmission
            issn:
               1435-1463
               0300-9564
            volumeNumber:107
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer-Verlag
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:H. J. Stuerenburg
               affiliation:
                     name:Neurological Department, University Hospital Hamburg – Eppendorf, Federal Republic of Germany
                     address:
                        name:Neurological Department, University Hospital Hamburg – Eppendorf, Federal Republic of Germany, , DE
                        type:PostalAddress
                     type:Organization
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:CSF copper concentrations, blood-brain barrier function, and coeruloplasmin synthesis during the treatment of Wilson's disease
      description: During the treatment of four patients with cerebral manifestation of Wilson's disease, we measured the copper concentration in the cerebrospinal fluid (CSF) and serum, the serum coeruloplasmin concentration, the free copper concentration in the serum, and the albumin ratio CSF/serum (AR). These measurements were treated as indicators of the copper-related toxic effects on the brain and the blood-brain barrier (BBB). The half – life of the decrease in the CSF copper concentration during therapy was 23.5 ± 5.78 months (mean ± S.E.M.). The therapeutic – target – copper concentration in the CSF (mean normal concentration) is below 20 μg/l. The average length of therapy needed to normalize CSF – copper values in our patients with an average initial value of 76.25 μg/L was 47 month. During the first 10 month of treatment there was an increase in all cases of the measured disturbance in the blood-brain barrier (measured as the ratio of albumin in CSF to albumin in serum, AR). All patients showed an initial worsening of the neurological condition, on average after 1.75 ± 0.25 months. The maximal rise in AR, from the initial values, was on average 18.4 ± 5.08%; this maximum was reached after an average of 6.9 ± 1.5 months. The AR normalized during therapy, indicating a reduction in toxicity in the blood-brain barrier region. The extent of the AR increases in individual patients did not correlate significantly with CSF copper half-life, serum copper half-life, the initial half – life of the reduction in the ratio (copper in serum)/(coeruloplasmin in serum), the initial copper concentration in CSF or serum, the initial free copper concentration in serum, or the initial dose of penicillamine (within the first 2 months). We conclude that the normalization of the CSF copper concentration in patients with the cerebral manifestation of Wilson's disease is a slow process, even if therapy is sufficient. The initial worsening of the neurological condition which has often been reported may be reflected in the disturbance of blood-brain barrier function, which we have measured here for the first time (using the parameter of the albumin ratio CSF/serum). Based on repeated measurements of the AR during the course of treatment it seems that the brain toxicity of mobilized copper can be assessed and the therapy adjusted.
      datePublished:
      dateModified:
      pageStart:321
      pageEnd:329
      sameAs:https://doi.org/10.1007/s007020050026
      keywords:
         Keywords: Wilson's disease, copper, coeruloplasmin, blood-brain-barrier, albumin ratio.
         Neurology
         Psychiatry
         Neurosciences
      image:
      isPartOf:
         name:Journal of Neural Transmission
         issn:
            1435-1463
            0300-9564
         volumeNumber:107
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer-Verlag
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:H. J. Stuerenburg
            affiliation:
                  name:Neurological Department, University Hospital Hamburg – Eppendorf, Federal Republic of Germany
                  address:
                     name:Neurological Department, University Hospital Hamburg – Eppendorf, Federal Republic of Germany, , DE
                     type:PostalAddress
                  type:Organization
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Journal of Neural Transmission
      issn:
         1435-1463
         0300-9564
      volumeNumber:107
Organization:
      name:Springer-Verlag
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Neurological Department, University Hospital Hamburg – Eppendorf, Federal Republic of Germany
      address:
         name:Neurological Department, University Hospital Hamburg – Eppendorf, Federal Republic of Germany, , DE
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:H. J. Stuerenburg
      affiliation:
            name:Neurological Department, University Hospital Hamburg – Eppendorf, Federal Republic of Germany
            address:
               name:Neurological Department, University Hospital Hamburg – Eppendorf, Federal Republic of Germany, , DE
               type:PostalAddress
            type:Organization
PostalAddress:
      name:Neurological Department, University Hospital Hamburg – Eppendorf, Federal Republic of Germany, , DE
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(25)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

3.38s.

LINK . SPRINGER . COM {}